Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
Accelerating sustainability in Indian pharma industry
Subscribe To Our Newsletter & Stay Updated
